HDAC9 and neoplasm: Histone deacetylase (HDAC) inhibitors have been shown to enhance interferon signaling and promote immune cell infiltration, thereby reversing the extrinsic immunosuppressive conditions within the tumor microenvironment and improving responsiveness in tumors that are resistant to immunotherapy.